Categories
Astec LifeSciences Limited — Updates, 27-04-2026: Press Release
27-04-2026 · 08:19 pm
Astec LifeSciences reports robust Q4 FY26. Consolidated income jumped 34% to ₹161.3 Cr, with EBITDA surging 87% to ₹11.8 Cr. For FY26, EBITDA turned positive at ₹0.5 Cr from a significant ₹60.6 Cr loss, showing strong operational recovery.
No comments yet. Be the first to comment!